[
    [
        {
            "time": "",
            "original_text": "A股医药生物公司研发实力排行榜：恒瑞医药、复星医药、君实生物研发投入居前三，药明康德研发人员数量最多",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "复星医药",
                    "君实生物",
                    "药明康德",
                    "研发投入",
                    "研发人员"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "A股医药生物公司研发实力排行榜：恒瑞医药、复星医药、君实生物研发投入居前三，药明康德研发人员数量最多",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "狂砸近70亿！高瓴最终还是买这家CDMO了，为什么我们提前预判到机会？",
            "features": {
                "keywords": [
                    "高瓴",
                    "CDMO",
                    "投资",
                    "收购"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "狂砸近70亿！高瓴最终还是买这家CDMO了，为什么我们提前预判到机会？",
                "Correlation": 7,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 6,
                "Market_Scope": 7,
                "Time_Proximity": 8,
                "Headline_Structure": 10,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "快讯 | 药明生物与药明康德子公司合全药业成立合资公司，从事抗体偶联药物（ADCs）等生物偶联药物CDMO服务",
            "features": {
                "keywords": [
                    "药明生物",
                    "药明康德",
                    "合全药业",
                    "合资公司",
                    "CDMO",
                    "ADCs"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "快讯 | 药明生物与药明康德子公司合全药业成立合资公司，从事抗体偶联药物（ADCs）等生物偶联药物CDMO服务",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 6,
                "Time_Proximity": 10,
                "Headline_Structure": 7,
                "Source_Recency": 10
            }
        },
        {
            "time": "",
            "original_text": "人口系列1：无法避免的人力成本上涨",
            "features": {
                "keywords": [
                    "人口",
                    "人力成本",
                    "上涨"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "经济",
                    "劳动力市场"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "人口系列1：无法避免的人力成本上涨",
                "Correlation": 4,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 7,
                "Entity_Density": 2,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "药明生物：与合全药业正式成立合资公司药明合联",
            "features": {
                "keywords": [
                    "药明生物",
                    "合全药业",
                    "合资公司",
                    "药明合联"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "药明生物：与合全药业正式成立合资公司药明合联",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "药明康德(02359)将每10股转增2股派3.63元",
            "features": {
                "keywords": [
                    "药明康德",
                    "转增",
                    "派息"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "药明康德(02359)将每10股转增2股派3.63元",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 6,
                "Source_Recency": 10
            }
        }
    ]
]